Eli Lilly and Company $LLY Shares Bought by Secure Asset Management LLC

Secure Asset Management LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 5.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,181 shares of the company’s stock after purchasing an additional 389 shares during the quarter. Eli Lilly and Company accounts for 1.0% of Secure Asset Management LLC’s investment portfolio, making the stock its 23rd biggest position. Secure Asset Management LLC’s holdings in Eli Lilly and Company were worth $8,309,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of LLY. Coastal Bridge Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $2,959,000. Mosaic Family Wealth Partners LLC lifted its position in shares of Eli Lilly and Company by 70.6% during the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock worth $4,144,000 after purchasing an additional 1,430 shares in the last quarter. Moran Wealth Management LLC boosted its stake in shares of Eli Lilly and Company by 85.6% in the second quarter. Moran Wealth Management LLC now owns 20,903 shares of the company’s stock valued at $25,072,000 after purchasing an additional 9,638 shares during the period. Generali Investments Management Co LLC boosted its stake in shares of Eli Lilly and Company by 17.5% in the second quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company’s stock valued at $12,258,000 after purchasing an additional 1,521 shares during the period. Finally, Amundi boosted its stake in shares of Eli Lilly and Company by 9.9% in the first quarter. Amundi now owns 5,055,025 shares of the company’s stock valued at $4,649,464,000 after purchasing an additional 454,549 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 3.6%

NYSE:LLY opened at $1,285.61 on Wednesday. The company has a market capitalization of $1.21 trillion, a price-to-earnings ratio of 43.14, a price-to-earnings-growth ratio of 1.65 and a beta of 0.46. Eli Lilly and Company has a one year low of $793.82 and a one year high of $1,311.75. The stock has a 50-day simple moving average of $1,181.79 and a 200 day simple moving average of $1,114.16. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The firm had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. During the same period in the previous year, the company earned $6.31 earnings per share. Eli Lilly and Company’s quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts predict that Eli Lilly and Company will post 33.56 EPS for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is currently owned by corporate insiders.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Goldman Sachs raised its price target to $1,413 from $1,371 and reiterated a Buy rating. The firm reportedly expects Lilly to exceed third-quarter earnings estimates and raise its outlook, supported by stronger international Mounjaro growth and increased Zepbound volumes through the Medicare GLP-1 Bridge program. Goldman Sachs raises Eli Lilly price target
• Positive Sentiment: Demand for Mounjaro and Zepbound remains the primary investment catalyst. Lilly’s GLP-1 portfolio is driving rapid revenue and earnings growth, while its oral obesity treatment Foundayo is approaching potential European approval and could support further market-share gains. Lilly valuation and GLP-1 growth ahead of earnings
• Positive Sentiment: Omvoh produced encouraging Phase 3 data in pediatric ulcerative colitis. Among Week 12 responders, 50% achieved clinical remission at Week 52, while 71.2% achieved symptomatic remission. Lilly plans to submit the results to regulators, potentially expanding Omvoh’s inflammatory bowel disease market. Lilly Omvoh pediatric ulcerative colitis trial
• Neutral Sentiment: Lilly reports third-quarter results on October 29. Expectations for another strong quarter are supporting momentum, but the elevated valuation leaves the stock sensitive to any earnings or guidance disappointment. Eli Lilly reaches high ahead of earnings
• Negative Sentiment: Investors continue to weigh risks from Lilly’s premium valuation, potential pricing competition with Novo Nordisk and heavy reliance on its obesity and diabetes franchise. A Pennsylvania lawsuit also alleges insulin price inflation, creating possible legal and reputational risks, although no outcome has been determined. Lilly insulin pricing lawsuit

Wall Street Analyst Weigh In

LLY has been the topic of a number of recent analyst reports. Guggenheim boosted their price objective on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a report on Friday, September 18th. Wall Street Zen cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Saturday. BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, October 1st. Weiss Ratings upgraded Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 15th. Finally, Berenberg Bank set a $1,400.00 target price on Eli Lilly and Company and gave the stock a “buy” rating in a research report on Tuesday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,314.93.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.